Adherence of bisphosphonate and decreased risk of clinical vertebral fracture in osteoporotic patients: A propensity score matching analysis

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM
Seihee Kim , Yoon-Sok Chung , Yunhwan Lee
{"title":"Adherence of bisphosphonate and decreased risk of clinical vertebral fracture in osteoporotic patients: A propensity score matching analysis","authors":"Seihee Kim ,&nbsp;Yoon-Sok Chung ,&nbsp;Yunhwan Lee","doi":"10.1016/j.afos.2022.05.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Bisphosphonate is associated with a decreased risk of vertebral fractures due to osteoporosis. However, there are limited studies on how poor compliance with bisphosphonate affects the risk of vertebral fractures in a nationwide cohort. We aim to evaluate whether adherence to bisphosphonate affects the risk of fracture in osteoporosis patients.</p></div><div><h3>Methods</h3><p>We used the data of the Korean National Health Insurance Service Senior Cohort. A total of 33,315 (medication possession ratio [MPR]: 50) osteoporosis patients were matched using the propensity score matching method: those who received low-dose bisphosphonate and those who received high-dose bisphosphonate. Twenty-two confounding variables, including age, socioeconomic status, medications prescribed, and underlying diseases that may affect the risk of fracture were adjusted for propensity score matching. The risk of vertebral fracture was assessed by Cox proportional hazards regression.</p></div><div><h3>Results</h3><p>Patients with a higher MPR showed a decreased vertebral fracture risk than those with a lower MPR (MPR 50 = hazard ratio [HR] 0.909; 95% confidence interval [CI] 0.877–0.942 P &lt; 0.001; MPR 70 = HR: 0.874, 95% CI: 0.838–0.913, P &lt; 0.001; MPR 90 = HR: 0.822, 95% CI: 0.780–0.866, P &lt; 0.001). MPR was associated with a decreased vertebral fracture risk in both groups with or without history of fracture. In the subgroup analysis, MPR was associated with a decreased vertebral fracture risk in women, in all ages, with or without T2DM, and with or without hypertension.</p></div><div><h3>Conclusions</h3><p>Higher MPR is associated with a lower vertebral fracture risk.</p></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"8 3","pages":"Pages 98-105"},"PeriodicalIF":2.5000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/55/main.PMC9577186.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osteoporosis and Sarcopenia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405525522000425","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 3

Abstract

Objectives

Bisphosphonate is associated with a decreased risk of vertebral fractures due to osteoporosis. However, there are limited studies on how poor compliance with bisphosphonate affects the risk of vertebral fractures in a nationwide cohort. We aim to evaluate whether adherence to bisphosphonate affects the risk of fracture in osteoporosis patients.

Methods

We used the data of the Korean National Health Insurance Service Senior Cohort. A total of 33,315 (medication possession ratio [MPR]: 50) osteoporosis patients were matched using the propensity score matching method: those who received low-dose bisphosphonate and those who received high-dose bisphosphonate. Twenty-two confounding variables, including age, socioeconomic status, medications prescribed, and underlying diseases that may affect the risk of fracture were adjusted for propensity score matching. The risk of vertebral fracture was assessed by Cox proportional hazards regression.

Results

Patients with a higher MPR showed a decreased vertebral fracture risk than those with a lower MPR (MPR 50 = hazard ratio [HR] 0.909; 95% confidence interval [CI] 0.877–0.942 P < 0.001; MPR 70 = HR: 0.874, 95% CI: 0.838–0.913, P < 0.001; MPR 90 = HR: 0.822, 95% CI: 0.780–0.866, P < 0.001). MPR was associated with a decreased vertebral fracture risk in both groups with or without history of fracture. In the subgroup analysis, MPR was associated with a decreased vertebral fracture risk in women, in all ages, with or without T2DM, and with or without hypertension.

Conclusions

Higher MPR is associated with a lower vertebral fracture risk.

Abstract Image

Abstract Image

Abstract Image

骨质疏松症患者坚持使用双膦酸盐和降低临床椎体骨折风险:倾向评分匹配分析
目的:双膦酸盐可降低骨质疏松所致椎体骨折的风险。然而,在全国范围内,关于双膦酸盐依从性差如何影响椎体骨折风险的研究有限。我们的目的是评估坚持使用双膦酸盐是否会影响骨质疏松症患者骨折的风险。方法采用韩国国民健康保险服务老年人队列数据。采用倾向评分匹配法对33,315例骨质疏松患者(药物占有比[MPR]: 50)进行低剂量双膦酸盐组与高剂量双膦酸盐组的匹配。22个混杂变量,包括年龄、社会经济地位、处方药物和可能影响骨折风险的潜在疾病,被调整为倾向评分匹配。采用Cox比例风险回归法评估椎体骨折的风险。结果MPR高的患者椎体骨折风险低于MPR低的患者(MPR 50 =危险比[HR] 0.909;95%置信区间[CI] 0.877-0.942 P <0.001;MPR 70 = HR: 0.874, 95% CI: 0.838 ~ 0.913, P <0.001;MPR 90 = HR: 0.822, 95% CI: 0.780-0.866, P <0.001)。无论是否有骨折史,MPR均与椎体骨折风险降低相关。在亚组分析中,MPR与女性椎体骨折风险降低相关,不论年龄大小,不论有无T2DM,不论有无高血压。结论较高的MPR与较低的椎体骨折风险相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Osteoporosis and Sarcopenia
Osteoporosis and Sarcopenia Orthopedics, Sports Medicine and Rehabilitation, Endocrinology, Diabetes and Metabolism, Obstetrics, Gynecology and Women's Health, Geriatrics and Gerontology
自引率
5.00%
发文量
23
审稿时长
66 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信